Zenas BioPharma, Inc. (ZBIO)
| Market Cap | 417.09M |
| Revenue (ttm) | 15.00M |
| Net Income (ttm) | -162.76M |
| Shares Out | 41.83M |
| EPS (ttm) | -7.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 126,313 |
| Open | 10.10 |
| Previous Close | 10.33 |
| Day's Range | 9.70 - 10.69 |
| 52-Week Range | 5.83 - 26.25 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 32.29 (+223.55%) |
| Earnings Date | Jun 24, 2025 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated a... [Read more]
Financial Performance
In 2024, Zenas BioPharma's revenue was $5.00 million, a decrease of -90.00% compared to the previous year's $50.00 million. Losses were -$156.99 million, 322.9% more than in 2023.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ZBIO stock is "Strong Buy." The 12-month stock price forecast is $32.29, which is an increase of 223.55% from the latest price.
News
FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
LOS ANGELES , June 16, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purch...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options
ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
LOS ANGELES , June 11, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise ...
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the d...
Reminder from Cohen Milstein: Zenas BioPharma (ZBIO) Lead Plaintiff Deadline in ZBIO Stock Drop Suit Approaching
Zenas BioPharma investors are encouraged to call Cohen Milstein's Molly Bowen, Esq. about becoming a lead plaintiff in the ZBIO stock drop class action.
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -
Zenas BioPharma Investors: Cohen Milstein Highlights June 16 Deadline to Seek Lead Plaintiff Role in Securities Lawsuit
Zenas BioPharma investors have until June 16 to sign up to become a Lead Plaintiff in this securities class action. For more information, call Molly Bowen.
Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit
Cohen Milstein reminds Zenas BioPharma (ZBIO) investors of an opportunity to lead a securities fraud class action. Lead plaintiff deadline - June 16, 2025.
Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related Fraud
WASHINGTON, D.C., May 01, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ: ZBIO) entered the public markets in September 2024 with a $17 per share debut and bold projections.
Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses
WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential securities fraud claims on behalf of investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who ...
Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses
WASHINGTON, April 21, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential claims on behalf of investors who purchased securities of Zenas BioPharma, Inc. (NASDAQ: ZB...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. (ZBIO)
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachus...
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the...
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst
Dual inhibition of CD19 and FcyRIIb leads to broader B-cell depletion coverage compared to that of other CD19 and CD20 inhibitors. Zenas BioPharma, Inc.'s topline 12-week results, from the phase 2 Moo...
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy Dr. Laken brings over 25 years of leadership experience in research, dev...
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
On Thursday, Wedbush initiated coverage on Zenas BioPharma, Inc. ZBIO, a clinical-stage global biopharmaceutical company focused on developing therapies for autoimmune disease.
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies–
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in...